Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Anemia Associated With Chronic Kidney Disease Clinical Trial

Official title:

An Open-label, Multicenter Study Investigating the Efficacy, Safety and Pharmacokinetics of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04621331
• Other study ID #: FGN-PED-CLIN-02
• Status: Withdrawn
• Phase: Phase 3
• Start date: May 23, 2022
• Est. completion date: May 23, 2022

Study information

• Verified date: June 2022
• Source: FibroGen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who are receiving either hemodialysis (HD) or peritoneal dialysis (PD). The study will enroll patients between the ages of 2 to <18 years in two sequential cohorts, with the older cohort of ages 12 to <18 years enrolled first. Approximately 30 patients will be enrolled in each age-based cohort.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 23, 2022
• Est. primary completion date: May 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Important Inclusion Criteria:

• Clinically stable CKD in the opinion of the investigator.

• Estimated glomerular filtration rate (Bedside Schwartz formula) of < 60 ml/min/1.73 m2 (stage 3, 4 and 5 CKD) for non-dialysis patients, or patients who are receiving chronic dialysis (hemodialysis or peritoneal dialysis) for ESRD.

• For ESA-naïve patients (either NDD or DD; ESA-naïve is defined as those patients whose total duration of prior ESA exposure is = 3 weeks within the preceding 12 weeks at the time informed consent is obtained), mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be < 11.0 g/dL. For patients currently receiving stable ESA dosing who will discontinue ESA and convert to roxadustat during study, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be = 10.0 g/dL and = 12.5 g/dL.

• Ferritin >50 ng/mL and transferrin saturation >10% (obtained from screening visit).

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2x upper limit of normal (ULN) and total bilirubin (Tbili) =1.5x ULN at randomization (obtained from screening visit).

• Serum folate and vitamin B12 > LLN (obtained from screening visit).

Important Exclusion Criteria:

• Uncontrolled hypertension as judged by the principal investigator in the 2 weeks prior to screening.

• Known hematologic disease other than anemia associated with CKD.

• Known malignancy within the past 5 years before screening.

• Any prior organ transplant or any planned organ transplant during the study period.

• Any RBC transfusion during the past 8 weeks before screening.

• Any condition leading to significant blood loss (e.g., gastrointestinal bleeding, surgical procedures) within 8 weeks before screening or during the screening period.

• History of chronic liver disease.

• Pure red cell aplasia (PRCA) or history of PRCA.

• History of epileptic seizures.

• History of hyperlipidemia or significant thrombotic/thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).

• History of thrombosis of an arteriovenous fistula/graft within 12 weeks prior to enrollment.

• Any active systemic or significant infection or episode of peritonitis within 30 days of screening.

• Any statin use within 30 days of screening.

• Any prior exposure to roxadustat or any other HIF-PH inhibitor.

Related Conditions & MeSH terms

• Anemia
• Anemia Associated With Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Roxadustat
HIF-PH inhibitor for treatment of anemia in CKD

Locations

Country	Name	City	State
United States	Ann and Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Investigative site	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
FibroGen	AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with mean Hb = 11.0 g/dL		Averaged over weeks 16-24
Secondary	Mean change in Hb		Baseline to averaged over weeks 16-24
Secondary	Time to first Hb response (this only applies to NDD patients)		From baseline without rescue therapy